Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1090, New York, NY, 10029, USA,
Curr Infect Dis Rep. 2013 Dec;15(6):504-13. doi: 10.1007/s11908-013-0371-z.
Multidrug-resistant organisms (MDROs) are an emerging threat in solid organ transplantation (SOT). The changing epidemiology of these MDROs is reviewed along with the growing evidence regarding risk factors and outcomes associated with both colonization and infection in SOT. The management of these infections is complicated by the lack of antimicrobial agents available to treat these infections, and only a handful of new agents, especially for the treatment of MDR GNR infections, are being evaluated in clinical trials. Due to the increased prevalence of MDROs and limited treatment options, as well as organ shortages, transplant candidacy and use of organs from donors with evidence of MDRO colonization and/or infection remain controversial. Increasing collaboration between transplant programs, individual practitioners, infection control programs, and researchers in antimicrobial development will be needed to face this challenge.
多药耐药菌(MDROs)是实体器官移植(SOT)中出现的新威胁。本文回顾了这些 MDROs 的流行病学变化,以及与 SOT 中定植和感染相关的风险因素和结果的不断增加的证据。由于缺乏可用于治疗这些感染的抗菌药物,这些感染的管理变得复杂,只有少数几种新药物,特别是用于治疗耐多药革兰氏阴性菌感染的药物,正在临床试验中进行评估。由于 MDROs 的流行率增加和治疗选择有限,以及器官短缺,因此对于 MDRO 定植和/或感染证据的供者器官的移植候选资格和使用仍然存在争议。需要增加移植项目、个体从业者、感染控制项目和抗菌药物开发研究人员之间的合作,以应对这一挑战。